(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 18.77% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Dynavax Technologies's revenue in 2025 is $294,621,000.On average, 1 Wall Street analysts forecast DVAX's revenue for 2025 to be $40,369,913,724, with the lowest DVAX revenue forecast at $40,369,913,724, and the highest DVAX revenue forecast at $40,369,913,724. On average, 1 Wall Street analysts forecast DVAX's revenue for 2026 to be $50,088,040,728, with the lowest DVAX revenue forecast at $50,088,040,728, and the highest DVAX revenue forecast at $50,088,040,728.
In 2027, DVAX is forecast to generate $59,166,137,868 in revenue, with the lowest revenue forecast at $59,166,137,868 and the highest revenue forecast at $59,166,137,868.